Evidence map›Paper›PMID 27670785›Full record

ArticleBMC research notes2016

Infrared-emitting, peptidase-resistant fluorescent ligands of the bradykinin B

Lajos Gera, Xavier Charest-Morin, Melissa Jean, Hélène Bachelard, François Marceau

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. A Robust Bioassay of the Human Bradykinin BPharmaceuticals (Basel, Switzerland) · 2021
    Review
  2. Review
  3. Frontiers in pharmacology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lajos GeraDepartment of Biochemistry, University of Colorado Denver, Aurora, CO, 80045, USA.
Xavier Charest-MorinAxe maladies infectieuses et immunitaires, Centre de recherche, CHU de Québec Université Laval, Quebec, QC, G1V 4G2, Canada.
Melissa JeanAxe endocrinologie et néphrologie, Centre de recherche, CHU de Québec Université Laval, Quebec, QC, G1V 4G2, Canada.
Hélène BachelardAxe endocrinologie et néphrologie, Centre de recherche, CHU de Québec Université Laval, Quebec, QC, G1V 4G2, Canada.
François MarceauCentre de Recherche du CHU de Québec (CHUL), Room T1-49, 2705 Boulevard Laurier, Quebec City, QC, G1V 4G2, Canada. francois.marceau@crchul.ulaval.ca.ORCID http://orcid.org/0000-0003-1691-6083
Université Laval · CACentre hospitalier universitaire de Québec · CAUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have previously reported the design, pharmacological properties and imaging application of bradykinin (BK) B

resultsThe antagonist B-9430 (D-Arg-[Hyp

conclusionsDespite a propensity for non-specific binding when used at high concentrations and limited sensitivity, Cy7-conjugated peptidase-resistant B

Indexed as

Bradykinin B2 receptorsCyanine dye 7CytofluorometryFluorescenceHuman umbilical veinMicroscopy

Identifiers

PMID27670785
PMCPMC5037861
OpenAlexW2527468127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.